Clinical Trial Update: Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 long-term extension study evaluating ACC-001 in mild to moderate Alzheimer’s disease completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ACC-001

Snippet

Sponsor: Pfizer | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-03-25